New targeted therapy duo enters human trials for advanced breast cancer
NCT ID NCT07121244
First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times
Summary
This early-phase study tests two related drugs: one to help see tumors on scans (68Ga-R11228) and another to deliver radiation directly to cancer cells (177Lu-R11228). It is for people with advanced hormone-receptor positive breast cancer that has spread or come back. The main goal is to check safety and find the right dose in about 62 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCOREGIONALLY RECURRENT HORMONE-RECEPTOR POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Melbourne Theranostic Innovation Centre (MTIC)
Melbourne, Australia
-
United Theranostics
Glen Burnie, Maryland, 21061, United States
-
United Theranostics Princeton
Princeton, New Jersey, 08540, United States
-
University Hospital Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
University of Utah - Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood test monitoring may be as good as scans for breast cancer patients
- Morning or evening? new study tests best time for cancer pill.
- Radioactive tracer could spot hidden breast cancer tumors
- New drug combo shows promise in Hard-to-Treat breast cancer
- New drug avasopasem joins fight against metastatic breast cancer